{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:20:23Z","timestamp":1791602423898,"version":"4.3.4"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T00:00:00Z","timestamp":1519084800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s11154-018-9443-6","type":"journal-article","created":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T16:39:19Z","timestamp":1519144759000},"page":"145-158","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important"],"prefix":"10.1007","volume":"19","author":[{"given":"Xi-Feng","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde P.","family":"Spampatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Spitzweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph J.","family":"Auernhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,20]]},"reference":[{"issue":"5","key":"9443_CR1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1159\/000481390","volume":"33","author":"G Kl\u00f6ppel","year":"2017","unstructured":"Kl\u00f6ppel G. Neuroendocrine neoplasms: dichotomy. Origin Classif Visc Med. 2017;33(5):324\u201330.","journal-title":"Origin Classif Visc Med"},{"issue":"3","key":"9443_CR2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000457956","volume":"105","author":"A Perren","year":"2017","unstructured":"Perren A, Couvelard A, Scoazec JY, Costa F, Borbath I, Delle Fave G, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Pathology: diagnosis and prognostic stratification. Neuroendocrinology. 2017;105(3):196\u2013200.","journal-title":"Neuroendocrinology"},{"issue":"4","key":"9443_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s11154-017-9438-8","volume":"18","author":"Christian Fottner","year":"2017","unstructured":"Fottner C, Ferrata M, Weber MM. Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): When to consider, how to diagnose? Rev Endocr Metab Disord. 2017; https:\/\/doi.org\/10.1007\/s11154-017-9438-8 .","journal-title":"Reviews in Endocrine and Metabolic Disorders"},{"key":"9443_CR4","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1210\/er.2003-0014","volume":"25","author":"GA Kaltsas","year":"2004","unstructured":"Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25:458\u2013511.","journal-title":"Endocr Rev"},{"issue":"9","key":"9443_CR5","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/annonc\/mdq022","volume":"21","author":"R Garcia-Carbonero","year":"2010","unstructured":"Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, D\u00edaz-P\u00e9rez JA, Mart\u00ednez Del Prado MP, Alonso Ordu\u00f1a V, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol. 2010;21(9):1794\u2013803.","journal-title":"Ann Oncol"},{"issue":"4","key":"9443_CR6","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000242109","volume":"90","author":"U Ploeckinger","year":"2009","unstructured":"Ploeckinger U, Kloeppel G, Wiedenmann B. Lohmann R; representatives of 21 German NET Centers. The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors. Neuroendocrinology. 2009;90(4):349\u201363.","journal-title":"Neuroendocrinology"},{"issue":"9","key":"9443_CR7","doi-asserted-by":"crossref","first-page":"R423","DOI":"10.1530\/ERC-16-0200","volume":"23","author":"GK Dimitriadis","year":"2016","unstructured":"Dimitriadis GK, Weickert MO, Randeva HS, Kaltsas G, Grossman A. Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2016;23(9):R423\u201336.","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"9443_CR8","doi-asserted-by":"crossref","first-page":"R173","DOI":"10.1530\/ERC-17-0036","volume":"24","author":"GK Dimitriadis","year":"2017","unstructured":"Dimitriadis GK, Angelousi A, Weickert MO, Randeva HS, Kaltsas G, Grossman A. Paraneoplastic endocrine syndromes. Endocr Relat Cancer. 2017;24(6):R173\u201390.","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"9443_CR9","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1200\/JCO.2012.44.5924","volume":"31","author":"JR Strosberg","year":"2013","unstructured":"Strosberg JR, Weber JM, Feldman M, Coppola D, Meredith K, Kvols LK. Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors. J Clin Oncol. 2013;31(4):420\u20135.","journal-title":"J Clin Oncol"},{"issue":"1","key":"9443_CR10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.surg.2013.08.002","volume":"155","author":"S Crippa","year":"2014","unstructured":"Crippa S, Partelli S, Zamboni G, Scarpa A, Tamburrino D, Bassi C, et al. Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors. Surgery. 2014;155(1):145\u201353.","journal-title":"Surgery"},{"issue":"5","key":"9443_CR11","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/S2213-8587(17)30401-1","volume":"6","author":"Christoph J Auernhammer","year":"2018","unstructured":"Auernhammer CJ, Spitzweg C, Angele MK, Boeck S, Grossman A, N\u00f6lting S, et al. Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. Auernhammer Lancet Diabetes Endocrinol. 2017; https:\/\/doi.org\/10.1016\/S2213-8587(17)30401-1 .","journal-title":"The Lancet Diabetes & Endocrinology"},{"issue":"4","key":"9443_CR12","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","volume":"18","author":"DM Halperin","year":"2017","unstructured":"Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18(4):525\u201334.","journal-title":"Lancet Oncol."},{"issue":"2","key":"9443_CR13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/cen.13364","volume":"87","author":"WT Zandee","year":"2017","unstructured":"Zandee WT, van Adrichem RC, Kamp K, Feelders RA, van Velthuysen MF, de Herder WW. Incidence and prognostic value of serotonin secretion in pancreatic neuroendocrine tumours. Clin Endocrinol. 2017;87(2):165\u201370. https:\/\/doi.org\/10.1111\/cen.13364 .","journal-title":"Clin Endocrinol"},{"issue":"2","key":"9443_CR14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000443171","volume":"103","author":"M Falconi","year":"2016","unstructured":"Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103(2):153\u201371.","journal-title":"Neuroendocrinology"},{"issue":"2","key":"9443_CR15","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1210\/jc.2015-2436","volume":"101","author":"J Crona","year":"2016","unstructured":"Crona J, Norl\u00e9n O, Antonodimitrakis P, Welin S, St\u00e5lberg P, Eriksson B. Multiple and Secondary Hormone Secretion in Patients With Metastatic Pancreatic Neuroendocrine Tumours. J Clin Endocrinol Metab. 2016;101(2):445\u201352. https:\/\/doi.org\/10.1210\/jc.2015-2436 .","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"9443_CR16","doi-asserted-by":"publisher","first-page":"R219","DOI":"10.1530\/EJE-17-0295","volume":"177","author":"I Huguet","year":"2017","unstructured":"Huguet I, Grossman A. Management Of endocrine disease: Flushing: current concepts. J Endocrinol. 2017;177(5):R219\u201329. https:\/\/doi.org\/10.1530\/EJE-17-0295 .","journal-title":"J Endocrinol"},{"issue":"3","key":"9443_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000461583","volume":"105","author":"G Kaltsas","year":"2017","unstructured":"Kaltsas G, Caplin M, Davies P, Ferone D, Garcia-Carbonero R, Grozinsky-Glasberg S, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Pre- and perioperative therapy in patients with neuroendocrine tumors. Neuroendocrinology. 2017;105(3):245\u201354. https:\/\/doi.org\/10.1159\/000461583 .","journal-title":"Neuroendocrinology"},{"issue":"10","key":"9443_CR18","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.jacc.2016.12.030","volume":"69","author":"J Davar","year":"2017","unstructured":"Davar J, Connolly HM, Caplin ME, Pavel M, Zacks J, Bhattacharyya S, et al. Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors. An Expert Statement J Am Coll Cardiol. 2017;69(10):1288\u2013304. https:\/\/doi.org\/10.1016\/j.jacc.2016.12.030 .","journal-title":"An Expert Statement J Am Coll Cardiol"},{"issue":"5","key":"9443_CR19","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1159\/000440621","volume":"103","author":"G Bouma","year":"2016","unstructured":"Bouma G, van Faassen M, Kats-Ugurlu G, de Vries EG, Kema IP, Walenkamp AM. Niacin (Vitamin B3) supplementation in patients with serotonin-producing neuroendocrine tumor. Neuroendocrinology. 2016;103(5):489\u201394. https:\/\/doi.org\/10.1159\/000440621 .","journal-title":"Neuroendocrinology"},{"issue":"10","key":"9443_CR20","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1111\/j.1572-0241.2005.00268.x","volume":"100","author":"GM Shah","year":"2005","unstructured":"Shah GM, Shah RG, Veillette H, Kirkland JB, Pasieka JL, Warner RR. Biochemical assessment of niacin deficiency among carcinoid cancer patients. Am J Gastroenterol. 2005;100(10):2307\u201314.","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"9443_CR21","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/bjc.2014.468","volume":"111","author":"R Dobson","year":"2014","unstructured":"Dobson R, Burgess MI, Valle JW, Pritchard DM, Vora J, Wong C, et al. Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality. Br J Cancer. 2014;111(9):1703\u20139.","journal-title":"Br J Cancer"},{"issue":"6","key":"9443_CR22","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0000000000000850","volume":"46","author":"JR Strosberg","year":"2017","unstructured":"Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, et al. The North American neuroendocrine tumor society consensus guidelines for surveillance ad medical management of midgut neuroendocrine tumors. Pancreas. 2017;46(6):707\u201314.","journal-title":"Pancreas"},{"key":"9443_CR23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/CIRCIMAGING.109.886846","volume":"3","author":"S Bhattacharyya","year":"2010","unstructured":"Bhattacharyya S, Toumpanakis C, Burke M, Taylor AM, Caplin ME, Davar J. Features of carcinoid heart disease identified by 2- and 3-dimensional echocardiography and cardiac MRI. Circ Cardiovasc Imaging. 2010;3:103\u201311.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"24","key":"9443_CR24","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1002\/cncr.31079","volume":"123","author":"FM Laskaratos","year":"2017","unstructured":"Laskaratos FM, Rombouts K, Caplin M, Toumpanakis C, Thirlwell C, Mandair D. Neuroendocrine tumors and fibrosis: An unsolved mystery? Cancer. 2017 Dec 15;123(24):4770\u201390.","journal-title":"Cancer"},{"issue":"3","key":"9443_CR25","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1530\/ERC-17-0282","volume":"25","author":"Anela Bla\u017eevi\u0107","year":"2018","unstructured":"Blazevic A, Zandee WT, Franssen GJH, Hofland J, Van Velthuysen MF, Hofland L, et al. Mesenteric fibrosis and palliative surgery in small intestinal neuroendocrine tumours. Endocr Relat Cancer. 2017; https:\/\/doi.org\/10.1530\/ERC-17-0282 .","journal-title":"Endocrine-Related Cancer"},{"issue":"3","key":"9443_CR26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/qjmed\/hcp191","volume":"103","author":"MR Druce","year":"2010","unstructured":"Druce MR, Bharwani N, Akker SA, Drake WM, Rockall A, Grossman AB. Intra-abdominal fibrosis in a recent cohort of patients with neuroendocrine ('carcinoid') tumours of the small bowel. QJM. 2010;103(3):177\u201385.","journal-title":"QJM"},{"issue":"1","key":"9443_CR27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/bjs.10333","volume":"104","author":"K Daskalakis","year":"2017","unstructured":"Daskalakis K, Karakatsanis A, St\u00e5lberg P, Norl\u00e9n O, Hellman P. Clinical signs of fibrosis in small intestinal neuroendocrine tumours. Br J Surg. 2017;104(1):69\u201375.","journal-title":"Br J Surg"},{"issue":"3","key":"9443_CR28","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000472254","volume":"105","author":"Kjell Oberg","year":"2017","unstructured":"Oberg K, Couvelard A, Delle Fave G, Gross D, Grossman A, Jensen RT, Pape UF, Perren A, Rindi G, Ruszniewski P, Scoazec JY, Welin S, Wiedenmann B, Ferone D; Antibes Consensus Conference participants. ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Biochemical Markers. Neuroendocrinology 2017;105(3):201\u2013211.","journal-title":"Neuroendocrinology"},{"issue":"1","key":"9443_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00108-017-0360-7","volume":"59","author":"C. J. Auernhammer","year":"2017","unstructured":"Auernhammer CJ, Reincke M. [Functional diagnostics in endocrinology]. Internist (Berl). 2017. https:\/\/doi.org\/10.1007\/s00108-017-0360-7 .","journal-title":"Der Internist"},{"issue":"2","key":"9443_CR30","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000335591","volume":"95","author":"RT Jensen","year":"2012","unstructured":"Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95(2):98\u2013119.","journal-title":"Neuroendocrinology"},{"issue":"3","key":"9443_CR31","doi-asserted-by":"crossref","first-page":"515","DOI":"10.5114\/aoms.2016.60311","volume":"13","author":"P Gut","year":"2017","unstructured":"Gut P, Walig\u00f3rska-Stachura J, Czarnywojtek A, Sawicka-Gutaj N, B\u0105czyk M, Ziemnicka K, et al. Management of the hormonal syndrome of neuroendocrine tumors. Arch Med Sci. 2017;13(3):515\u201324.","journal-title":"Arch Med Sci"},{"issue":"6","key":"9443_CR32","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/MOG.0b013e328365efb1","volume":"29","author":"T Ito","year":"2013","unstructured":"Ito T, Igarashi H, Jensen RT. Zollinger-Ellison syndrome: recent advances and controversies. Curr Opin Gastroenterol. 2013;29(6):650\u201361.","journal-title":"Curr Opin Gastroenterol"},{"issue":"3","key":"9443_CR33","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1517\/14656566.2013.767332","volume":"14","author":"T Ito","year":"2013","unstructured":"Ito T, Igarashi H, Uehara H, Jensen RT. Pharmacotherapy of Zollinger-Ellison syndrome. Expert Opin Pharmacother. 2013;14(3):307\u201321.","journal-title":"Expert Opin Pharmacother"},{"key":"9443_CR34","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0399-8320(04)95184-6","volume":"28","author":"N Levy-Bohbot","year":"2004","unstructured":"Levy-Bohbot N, Merle C, Goudet P, Delemer B, Calender A, Jolly D, et al. Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas,VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol Clin Biol. 2004;28:1075\u201381.","journal-title":"Gastroenterol Clin Biol"},{"issue":"12","key":"9443_CR35","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/jdv.13752","volume":"30","author":"AM John","year":"2016","unstructured":"John AM, Schwartz RA. Glucagonoma syndrome: a review and update on treatment. J Eur Acad Dermatol Venereol. 2016;30(12):2016\u201322.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"9443_CR36","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMicm1603135","volume":"376","author":"L Mountjoy","year":"2017","unstructured":"Mountjoy L, Kollmorgen D. Glucagonoma-Associated Rash. N Engl J Med. 2017;376(10):e18.","journal-title":"N Engl J Med"},{"issue":"2","key":"9443_CR37","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2337\/db16-0994","volume":"66","author":"JJ Holst","year":"2017","unstructured":"Holst JJ, Wewer Albrechtsen NJ, Pedersen J, Knop FK. Glucagon and amino acids are linked in a mutual feedback cycle: The liver-\u03b1-cell axis. Diabetes. 2017;66(2):235\u201340. https:\/\/doi.org\/10.2337\/db16-0994 .","journal-title":"Diabetes"},{"issue":"3","key":"9443_CR38","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/jamadermatol.2015.3538","volume":"152","author":"E Thomaidou","year":"2016","unstructured":"Thomaidou E, Nahmias A, Gilead L, Zlotogorski A, Ramot Y. rapid clearance of necrolytic migratory erythema following intravenous administration of amino acids. JAMA Dermatol. 2016;152(3):345\u20136.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"9443_CR39","first-page":"451","volume":"176","author":"MV Davi","year":"2017","unstructured":"Davi MV, Cosaro E, Piacentini S, Reimondo G, Albiger N, Arnaldi G, et al. Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study. Eur J Endocrinol. 2017;176(4):451\u20139.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"9443_CR40","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ando.2012.09.004","volume":"73","author":"F Borson-Chazot","year":"2012","unstructured":"Borson-Chazot F, Garby L, Raverot G, Claustrat F, Raverot V, Sassolas G, et al. Acromegaly induced by ectopic secretion of GHRH: a review 30 years after GHRH discovery. Ann Endocrinol (Paris). 2012;73(6):497\u2013502.","journal-title":"Ann Endocrinol (Paris)"},{"issue":"4","key":"9443_CR41","first-page":"E84","volume":"5","author":"V Zhu","year":"2014","unstructured":"Zhu V, de Las MA, Janicek M, Hartshorn K. Hypercalcemia from metastatic pancreatic neuroendocrine tumor secreting 1,25-dihydroxyvitamin D. J Gastrointest Oncol. 2014;5(4):E84\u20137.","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"9443_CR42","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1053\/j.gastro.2011.12.009","volume":"143","author":"T Vandamme","year":"2012","unstructured":"Vandamme T, Kunnen J. Simoens M Hyperammonemic encephalopathy in diffuse liver metastasis: is this the end stage? Gastroenterology. 2012;143(1):e9\u2013e10.","journal-title":"Gastroenterology"},{"issue":"8","key":"9443_CR43","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1097\/MCG.0b013e3181d96aad","volume":"44","author":"V Broadbridge","year":"2010","unstructured":"Broadbridge V, Townsend A, Pittman K, Kimber R, Patterson W, Sukumaran S, et al. Reversing Hyperammonemia in Neuroendocrine Tumors. J Clin Gastroenterol. 2010;44(8):e186\u20139.","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"9443_CR44","first-page":"11","volume":"6","author":"KJ Willson","year":"2013","unstructured":"Willson KJ, Nott LM, Broadbridge VT, Price T. Hepatic encephalopathy associated with cancer or anticancer therapy. Gastrointest Cancer Res. 2013;6(1):11\u20136.","journal-title":"Gastrointest Cancer Res"},{"issue":"3","key":"9443_CR45","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s00270-009-9698-0","volume":"33","author":"JP Erinjeri","year":"2010","unstructured":"Erinjeri JP, Deodhar A, Thornton RH, Allen PJ, Getrajdman GI, Brown KT, et al. Resolution of hepatic encephalopathy following hepatic artery embolization in a patient with well-differentiated neuroendocrine tumor metastatic to the liver. Cardiovasc Intervent Radiol. 2010;33(3):610\u20134.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"16","key":"9443_CR46","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1080\/14656566.2016.1236916","volume":"17","author":"T Ito","year":"2016","unstructured":"Ito T, Lee L, Jensen RT. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. Expert Opin Pharmacother. 2016;17(16):2191\u2013205.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"9443_CR47","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jss.2015.05.048","volume":"198","author":"G Spolverato","year":"2015","unstructured":"Spolverato G, Bagante F, Wagner D, Buettner S, Gupta R, Kim Y, et al. Quality of life after treatment of neuroendocrine liver metastasis. J Surg Res. 2015;198(1):155\u201364.","journal-title":"J Surg Res"},{"issue":"6","key":"9443_CR48","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/MPA.0000000000000846","volume":"46","author":"JR Howe","year":"2017","unstructured":"Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, et al. The surgical management of small bowel neuroendocrine tumors: Consensus guidelines of the North American neuroendocrine tumor society. Pancreas. 2017;46(6):715\u201331.","journal-title":"Pancreas"},{"issue":"2","key":"9443_CR49","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","volume":"103","author":"M Pavel","year":"2016","unstructured":"Pavel M, O'Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial Neuroendocrine Neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103(2):172\u201385.","journal-title":"Neuroendocrinology"},{"issue":"1","key":"9443_CR50","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1055\/s-0033-1333651","volume":"30","author":"S Gupta","year":"2013","unstructured":"Gupta S. Intra-arterial liver-directed therapies for neuroendocrine hepatic metastases. Semin Intervent Radiol. 2013;30(1):28\u201338.","journal-title":"Semin Intervent Radiol"},{"issue":"4","key":"9443_CR51","doi-asserted-by":"crossref","first-page":"R151","DOI":"10.1530\/EJE-14-0630","volume":"172","author":"T Baere de","year":"2015","unstructured":"de Baere T, Deschamps F, Tselikas L, Ducreux M, Planchard D, Pearson E, et al. GEP-NETS update: Interventional radiology: role in the treatment of liver metastases from GEP-NETs. Eur J Endocrinol. 2015;172(4):R151\u201366.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"9443_CR52","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/hpb.12326","volume":"17","author":"A Kennedy","year":"2015","unstructured":"Kennedy A, Bester L, Salem R, Sharma RA, Parks RW, Ruszniewski P, et al. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB (Oxford). 2015;17(1):29\u201337. https:\/\/doi.org\/10.1111\/hpb.12326 .","journal-title":"HPB (Oxford)"},{"issue":"4","key":"9443_CR53","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s11154-017-9431-2","volume":"18","author":"Louis de Mestier","year":"2017","unstructured":"de Mestier L, Zappa M, Hentic O, Vilgrain V, Ruszniewski P. Liver transarterial embolizations in metastatic neuroendocrine tumors. Rev Endocr Metab Disord. 2017; https:\/\/doi.org\/10.1007\/s11154-017-9431-2 .","journal-title":"Reviews in Endocrine and Metabolic Disorders"},{"issue":"12","key":"9443_CR54","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1097\/RLU.0000000000001383","volume":"41","author":"B Cramer","year":"2016","unstructured":"Cramer B, Xing M, Kim HS. Prospective longitudinal quality of life assessment in patients with neuroendocrine tumor liver metastases treated with 90y radioembolization. Clin Nucl Med. 2016;41(12):e493\u20137.","journal-title":"Clin Nucl Med"},{"issue":"3","key":"9443_CR55","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000464292","volume":"105","author":"S Partelli","year":"2017","unstructured":"Partelli S, Bartsch DK, Capdevila J, Chen J, Knigge U, Niederle B, et al. ENETS consensus guidelines for standard of care in neuroendocrine tumours: surgery for small intestinal and pancreatic neuroendocrine tumours. Neuroendocrinology. 2017;105(3):255\u201365.","journal-title":"Neuroendocrinology"},{"issue":"2","key":"9443_CR56","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1001\/jamaoncol.2017.3326","volume":"4","author":"Kosmas Daskalakis","year":"2018","unstructured":"Daskalakis K, Karakatsanis A, Hessman O, Stuart HC, Welin S, Tiensuu Janson E, et al. Association of a prophylactic surgical approach to stage iv small intestinal neuroendocrine tumors with survival. JAMA Oncol. 2017 https:\/\/doi.org\/10.1001\/jamaoncol.2017.3326 .","journal-title":"JAMA Oncology"},{"issue":"1","key":"9443_CR57","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/EJE-14-0354","volume":"172","author":"T Alonso-Gordoa","year":"2015","unstructured":"Alonso-Gordoa T, Capdevila J, Grande E. GEP-NETs update: Biotherapy for neuroendocrine tumours. Eur J Endocrinol. 2015;172(1):R31\u201346.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"9443_CR58","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000471880","volume":"105","author":"M Pavel","year":"2017","unstructured":"Pavel M, Valle JW, Eriksson B, Rinke A, Caplin M, Chen J, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: systemic therapy - biotherapy and novel targeted agents. Neuroendocrinology. 2017;105(3):266\u201380.","journal-title":"Neuroendocrinology"},{"issue":"1","key":"9443_CR59","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.beem.2015.09.004","volume":"30","author":"A Rinke","year":"2016","unstructured":"Rinke A, Krug S. Neuroendocrine tumours - Medical therapy: Biological. Best Pract Res Clin Endocrinol Metab. 2016;30(1):79\u201391.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"9443_CR60","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2036.2009.04174.x","volume":"31","author":"IM Modlin","year":"2010","unstructured":"Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther. 2010;31(2):169\u201388.58.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"9443_CR61","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","volume":"35","author":"MH Kulke","year":"2017","unstructured":"Kulke MH, H\u00f6rsch D, Caplin ME, Anthony LB, Bergsland E, \u00d6berg K, et al. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. J Clin Oncol. 2017;35(1):14\u201323.","journal-title":"J Clin Oncol"},{"issue":"11","key":"9443_CR62","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.clinthera.2017.09.013","volume":"39","author":"L Anthony","year":"2017","unstructured":"Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, et al. understanding the patient experience with carcinoid syndrome: exit interviews from a randomized, placebo-controlled study of telotristat ethyl. Clin Ther. 2017;39(11):2158\u201368.","journal-title":"Clin Ther"},{"issue":"2","key":"9443_CR63","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. NETTER-1 trial investigators. phase 3 trial of 177lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335.","journal-title":"N Engl J Med"},{"issue":"16","key":"9443_CR64","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23(16):4617\u201324.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"9443_CR65","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000475526","volume":"105","author":"RJ Hicks","year":"2017","unstructured":"Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues. Neuroendocrinology. 2017;105(3):295\u2013309.","journal-title":"Neuroendocrinology"},{"issue":"1","key":"9443_CR66","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s00259-017-3816-z","volume":"45","author":"M Marinova","year":"2018","unstructured":"Marinova M, M\u00fccke M, Mahlberg L, Essler M, Cuhls H, Radbruch L, et al. Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30. Eur J Nucl Med Mol Imaging. 2018;45(1):38\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"9443_CR67","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1634\/theoncologist.2014-0120","volume":"19","author":"JR Strosberg","year":"2014","unstructured":"Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, et al. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist. 2014;19(9):930\u20136.","journal-title":"Oncologist"},{"key":"9443_CR68","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jclinane.2016.03.008","volume":"32","author":"EA Woltering","year":"2016","unstructured":"Woltering EA, Wright AE, Stevens MA, Wang YZ, Boudreaux JP, Mamikunian G, et al. Development of effective prophylaxis against intraoperative carcinoid crisis. J Clin Anesth. 2016;32:189\u201393.","journal-title":"J Clin Anesth"},{"issue":"1","key":"9443_CR69","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.surg.2015.05.036","volume":"159","author":"ME Condron","year":"2016","unstructured":"Condron ME, Pommier SJ, Pommier RF. Continuous infusion of octreotide combined with perioperative octreotide bolus does not prevent intraoperative carcinoid crisis. Surgery. 2016;159(1):358\u201365.","journal-title":"Surgery"},{"key":"9443_CR70","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-11-0367","volume":"19","author":"LK Kvols","year":"2012","unstructured":"Kvols LK, Oberg KE, O\u2019Dorisio TM, Mohideen P, de Herder WW, Arnold R, et al. Pasireotide (SOM230)shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer. 2012;19:657\u201366.","journal-title":"Endocr Relat Cancer"},{"key":"9443_CR71","doi-asserted-by":"publisher","first-page":"5075","DOI":"10.2147\/DDDT.S84177","volume":"9","author":"EM Wolin","year":"2015","unstructured":"Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse MA, et al. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther. 2015;9:5075\u201386. https:\/\/doi.org\/10.2147\/DDDT.S84177 .","journal-title":"Drug Des Devel Ther"},{"issue":"7","key":"9443_CR72","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s40265-017-0737-x","volume":"77","author":"A Markham","year":"2017","unstructured":"Markham A. Telotristat Ethyl: First Global Approval. Drugs. 2017 May;77(7):793\u20138.","journal-title":"Drugs"},{"issue":"18","key":"9443_CR73","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1080\/14656566.2016.1254191","volume":"17","author":"A Lamarca","year":"2016","unstructured":"Lamarca A, Barriuso J, McNamara MG, Hubner RA, Valle JW. Telotristat ethyl: a new option for the management of carcinoid syndrome. Expert Opin Pharmacother. 2016;17(18):2487\u201398.","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"9443_CR74","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00280-017-3462-y","volume":"80","author":"M Masab","year":"2017","unstructured":"Masab M, Saif MW. Telotristat ethyl: proof of principle and the first oral agent in the management of well-differentiated metastatic neuroendocrine tumor and carcinoid syndrome diarrhea. Cancer Chemother Pharmacol. 2017;80(6):1055\u201362.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"9443_CR75","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1634\/theoncologist.2015-0455","volume":"21","author":"J Molina-Cerrillo","year":"2016","unstructured":"Molina-Cerrillo J, Alonso-Gordoa T, Mart\u00ednez-S\u00e1ez O, Grande E. Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors. Oncologist. 2016;21(6):701\u20137.","journal-title":"Oncologist"},{"issue":"1","key":"9443_CR76","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1053\/j.gastro.2017.03.008","volume":"153","author":"SH Jiang","year":"2017","unstructured":"Jiang SH, Li J, Dong FY, Yang JY, Liu DJ, Yang XM, et al. Increased serotonin signaling contributes to the warburg effect in pancreatic tumor cells under metabolic stress and promotes growth of pancreatic tumors in mice. Gastroenterology. 2017;153(1):277\u2013291.e19.","journal-title":"Gastroenterology"},{"issue":"12","key":"9443_CR77","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1002\/cncr.25049","volume":"116","author":"B Svejda","year":"2010","unstructured":"Svejda B, Kidd M, Giovinazzo F, Eltawil K, Gustafsson BI, Pfragner R, et al. The 5-HT(2B) receptor plays a key regulatory role in both neuroendocrine tumor cell proliferation and the modulation of the fibroblast component of the neoplastic microenvironment. Cancer. 2010;116(12):2902\u201312.","journal-title":"Cancer"},{"issue":"21","key":"9443_CR78","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1002\/cncr.24533","volume":"115","author":"I Drozdov","year":"2009","unstructured":"Drozdov I, Kidd M, Gustafsson BI, Svejda B, Joseph R, Pfragner R, et al. Autoregulatory effects of serotonin on proliferation and signaling pathways in lung and small intestine neuroendocrine tumor cell lines. Cancer. 2009;115(21):4934\u201345.","journal-title":"Cancer"},{"issue":"11","key":"9443_CR79","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1084\/jem.20120408","volume":"209","author":"EC Nowak","year":"2012","unstructured":"Nowak EC, de Vries VC, Wasiuk A, Ahonen C, Bennett KA, Le Mercier I, et al. Tryptophan hydroxylase-1 regulates immune tolerance and inflammation. J Exp Med. 2012;209(11):2127\u201335.","journal-title":"J Exp Med"},{"issue":"8","key":"9443_CR80","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/apt.13570","volume":"43","author":"N Mottacki","year":"2016","unstructured":"Mottacki N, Simr\u00e9n M, Bajor A. Review article: bile acid diarrhoea - pathogenesis, diagnosis and management. Aliment Pharmacol Ther. 2016;43(8):884\u201398.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"9443_CR81","doi-asserted-by":"crossref","first-page":"332","DOI":"10.5009\/gnl14397","volume":"9","author":"M Camilleri","year":"2015","unstructured":"Camilleri M. Bile Acid diarrhea: prevalence, pathogenesis, and therapy. Gut Liver. 2015;9(3):332\u20139.","journal-title":"Gut Liver"},{"issue":"3","key":"9443_CR82","doi-asserted-by":"publisher","first-page":"227","DOI":"10.5152\/tjg.2016.15375","volume":"27","author":"S Liang","year":"2016","unstructured":"Liang S, Xu L, Zhang D, Wu Z. Effect of probiotics on small intestinal bacterial overgrowth in patients with gastric and colorectal cancer. Turk J Gastroenterol. 2016;27(3):227\u201332. https:\/\/doi.org\/10.5152\/tjg.2016.15375 .","journal-title":"Turk J Gastroenterol"},{"issue":"5","key":"9443_CR83","first-page":"883","volume":"4","author":"L Deng","year":"2016","unstructured":"Deng L, Liu Y, Zhang D, Li Y, Xu L. Prevalence and treatment of small intestinal bacterial overgrowth in postoperative patients with colorectal cancer.Mol. Clin Oncol. 2016;4(5):883\u20137.","journal-title":"Clin Oncol"},{"issue":"5","key":"9443_CR84","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/ajg.2017.46","volume":"112","author":"A Rezaie","year":"2017","unstructured":"Rezaie A, Buresi M, Lembo A, Lin H, McCallum R, Rao S, et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American consensus. Am J Gastroenterol. 2017;112(5):775\u201384. https:\/\/doi.org\/10.1038\/ajg.2017.46 .","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"9443_CR85","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/apt.13928","volume":"45","author":"L Gatta","year":"2017","unstructured":"Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther. 2017;45(5):604\u201316.","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"9443_CR86","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/apt.12479","volume":"38","author":"SC Shah","year":"2013","unstructured":"Shah SC, Day LW, Somsouk M, Sewell JL. Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2013;38(8):925\u201334.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1 Suppl","key":"9443_CR87","doi-asserted-by":"crossref","first-page":"38S","DOI":"10.1177\/0148607113520618","volume":"38","author":"VJ Kumpf","year":"2014","unstructured":"Kumpf VJ. Pharmacologic management of diarrhea in patients with short bowel syndrome. JPEN J Parenter Enteral Nutr. 2014;38(1 Suppl):38S\u201344S.","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"4","key":"9443_CR88","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/MCG.0000000000000814","volume":"51","author":"C Zhong","year":"2017","unstructured":"Zhong C, Qu C, Wang B, Liang S, Zeng B. Probiotics for Preventing and Treating Small Intestinal Bacterial Overgrowth: A Meta-Analysis and Systematic Review of Current Evidence. J Clin Gastroenterol. 2017;51(4):300\u201311.","journal-title":"J Clin Gastroenterol"},{"issue":"6","key":"9443_CR89","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/myc.12604","volume":"60","author":"U Roy","year":"2017","unstructured":"Roy U, Jessani LG, Rudramurthy SM, Gopalakrishnan R, Dutta S, Chakravarty C, et al. Seven cases of Saccharomyces fungaemia related to use of probiotics. Mycoses. 2017;60(6):375\u201380.","journal-title":"Mycoses"},{"issue":"1","key":"9443_CR90","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.mycmed.2017.09.003","volume":"28","author":"\u0130. Kara","year":"2018","unstructured":"Kara I, Y\u0131ld\u0131r\u0131m F, \u00d6zgen \u00d6, Ergani\u015f S, Aydo\u011fdu M, Dizbay M, G\u00fcrsel G, Kalkanci A. Saccharomyces cerevisiae fungemia after probiotic treatment in an intensive care unit patient. J Mycol Med. 2017. https:\/\/doi.org\/10.1016\/j.mycmed.2017.09.003 . \\.","journal-title":"Journal de Mycologie M\u00e9dicale"},{"issue":"5","key":"9443_CR91","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/tid.12587","volume":"18","author":"SA Cohen","year":"2016","unstructured":"Cohen SA, Woodfield MC, Boyle N, Stednick Z, Boeckh M, Pergam SA. Incidence and outcomes of bloodstream infections among hematopoietic cell transplant recipients from species commonly reported to be in over-the-counter probiotic formulations. Transpl Infect Dis. 2016;18(5):699\u2013705.","journal-title":"Transpl Infect Dis"},{"key":"9443_CR92","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.jacc.2015.09.014","volume":"66","author":"HM Connolly","year":"2015","unstructured":"Connolly HM, Schaff HV, Abel MD, et al. Early and late outcomes of Surgical treatment in Carcinoid Heart Disease. J Am Coll Cardiol. 2015;66:2189\u201396.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"9443_CR93","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s12471-017-1011-2","volume":"25","author":"EA Hart","year":"2017","unstructured":"Hart EA, Meijs TA, Meijer RCA, Dreijerink KM, Tesselaar ME, de Groot CA, et al. Carcinoid heart disease: a guide for screening and timing of surgical intervention. Neth Heart J. 2017;25(9):471\u20138. https:\/\/doi.org\/10.1007\/s12471-017-1011-2 .","journal-title":"Neth Heart J"},{"issue":"3","key":"9443_CR94","first-page":"349","volume":"25","author":"A Korach","year":"2016","unstructured":"Korach A, Grozinsky-Glasberg S, Atlan J, Dabah A, Atlan K, Rudis E, et al. Valve replacement in patients with carcinoid heart disease: choosing the right valve at the right time. J Heart Valve Dis. 2016;25(3):349\u201355.","journal-title":"J Heart Valve Dis"},{"key":"9443_CR95","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/ejcts\/ezu201","volume":"47","author":"SV Pislaru","year":"2015","unstructured":"Pislaru SV, Hussain I, Pellikka PA, et al. Misconceptions, diagnostic challenges and treatment opportunities in bioprosthetic valve thrombosis: lessons from a case series. Eur J Cardiothorac Surg. 2015;47:725\u201332.","journal-title":"Eur J Cardiothorac Surg"},{"key":"9443_CR96","first-page":"1046","volume":"16","author":"B Heidecker","year":"2015","unstructured":"Heidecker B, Moore P, Bergsland EK, et al. Transcatheter pulmonic valve replacement in carcinoid heart disease. Eur Heart J Cardiovasc Imaging. 2015;16:1046.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"9443_CR97","doi-asserted-by":"crossref","first-page":"341","DOI":"10.14503\/THIJ-15-5310","volume":"43","author":"P Loyalka","year":"2016","unstructured":"Loyalka P, Schechter M, Nascimbene A, et al. Transcatheter pulmonary valve replacement in a carcinoid Heart. Tex Heart Inst J. 2016;43:341\u20134.","journal-title":"Tex Heart Inst J"},{"key":"9443_CR98","first-page":"110","volume":"24","author":"L Conradi","year":"2015","unstructured":"Conradi L, Schaefer A, Mueller GC, et al. Carcinoid heart valve disease: transcatheter pulmonary valve-in-valve implantation in failing biological xenografts. J Heart Valve Dis. 2015;24:110\u20134.","journal-title":"J Heart Valve Dis"},{"key":"9443_CR99","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/ehjci\/jew249","volume":"17","author":"JN Khan","year":"2016","unstructured":"Khan JN, Doshi SN, Rooney SJ, et al. Transcatheter pulmonary and tricuspid valve-in-valve replacement for bioprosthesis degeneration in carcinoid heart disease. Eur Heart J Cardiovasc Imaging. 2016;17:114.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"1","key":"9443_CR100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40618-016-0536-3","volume":"40","author":"MV Davi","year":"2017","unstructured":"Davi MV, Pia A, Guarnotta V, Pizza G, Colao A. Faggiano A; NIKE Group. The treatment of hyperinsulinemic hypoglycaemia in adults: an update. J Endocrinol Investig. 2017;40(1):9\u201320.","journal-title":"J Endocrinol Investig"},{"issue":"4","key":"9443_CR101","doi-asserted-by":"crossref","first-page":"489","DOI":"10.14310\/horm.2002.1706","volume":"15","author":"A Matej","year":"2016","unstructured":"Matej A, Bujwid H, Wro\u0144ski J. Glycemic control in patients with insulinoma. Hormones (Athens). 2016;15(4):489\u201399.","journal-title":"Hormones (Athens)"},{"issue":"5","key":"9443_CR102","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/cen.13528","volume":"88","author":"Emily Brown","year":"2018","unstructured":"E1 B, D1 W, J2 E, V3 Y, DJ1 C. Multi-disciplinary management of refractory insulinomas. Clin Endocrinol. 2017; https:\/\/doi.org\/10.1111\/cen.13528 .","journal-title":"Clinical Endocrinology"},{"issue":"12","key":"9443_CR103","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/S1470-2045(17)30681-2","volume":"18","author":"P Ferolla","year":"2017","unstructured":"Ferolla P, Brizzi MP, Meyer T, Mansoor W, Mazieres J, Do Cao C, et al. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2017;18(12):1652\u201364. https:\/\/doi.org\/10.1016\/S1470-2045(17)30681-2 .","journal-title":"Lancet Oncol"},{"issue":"2","key":"9443_CR104","doi-asserted-by":"crossref","first-page":"271","DOI":"10.14310\/horm.2002.1639","volume":"15","author":"A Tirosh","year":"2016","unstructured":"Tirosh A, Stemmer SM, Solomonov E, Elnekave E, Saeger W, Ravkin Y, et al. Pasireotide for malignant insulinoma. Hormones (Athens). 2016;15(2):271\u20136.","journal-title":"Hormones (Athens)."},{"issue":"5","key":"9443_CR105","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1530\/EJE-12-1101","volume":"168","author":"V Bernard","year":"2013","unstructured":"Bernard V, Lombard-Bohas C, Taquet MC, Caroli-Bosc FX, Ruszniewski P, Niccoli P, et al. Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia. Eur J Endocrinol. 2013;168(5):665\u201374.","journal-title":"Eur J Endocrinol"},{"key":"9443_CR106","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cellsig.2017.04.018","volume":"36","author":"SZ Lutz","year":"2017","unstructured":"Lutz SZ, Ullrich A, H\u00e4ring HU, Ullrich S, Gerst F. Sunitinib specifically augments glucose-induced insulin secretion. Cell Signal. 2017;36:91\u20137.","journal-title":"Cell Signal"},{"issue":"6","key":"9443_CR107","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1586\/era.13.45","volume":"13","author":"J Chen","year":"2013","unstructured":"Chen J, Wang C, Han J, Luan Y, Cui Y, Shen R, et al. Therapeutic effect of sunitinib malate and its influence on blood glucose concentrations in a patient with metastatic insulinoma. Expert Rev Anticancer Ther. 2013;13(6):737\u201343.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"9443_CR108","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12916-016-0718-z","volume":"14","author":"C Scarpignato","year":"2016","unstructured":"Scarpignato C, Gatta L, Zullo A, Blandizzi C, SIF-AIGO-FIMMG Group. Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179.","journal-title":"BMC Med"},{"key":"9443_CR109","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.abb.2016.06.003","volume":"611","author":"Y Ogawa","year":"2016","unstructured":"Ogawa Y, Kawamura T, Shimada S. Zinc and skin biology. Arch Biochem Biophys. 2016;611:113\u20139.","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"9443_CR110","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1530\/EJE-14-0682","volume":"172","author":"L Mestier de","year":"2015","unstructured":"de Mestier L, Walter T, Brixi H, Lombard-Bohas C, Cadiot G. Sunitinib achieved fast and sustained control of VIPoma symptoms. Eur J Endocrinol. 2015;172(1):K1\u20133.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"9443_CR111","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/MPA.0b013e31825c53fa","volume":"42","author":"ME Bourcier","year":"2013","unstructured":"Bourcier ME, Vinik AI. Sunitinib for the treatment of metastatic paraganglioma and vasoactive intestinal polypeptide-producing tumor (VIPoma). Pancreas. 2013;42(2):348\u201352.","journal-title":"Pancreas"},{"issue":"8","key":"9443_CR112","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","volume":"100","author":"LK Nieman","year":"2015","unstructured":"Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO. Tabarin A; EndocrineSociety. Treatment of Cushing's Syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(8):2807\u201331.","journal-title":"J Clin Endocrinol Metab"},{"key":"9443_CR113","first-page":"1779","volume":"11","author":"H Sternlicht","year":"2015","unstructured":"Sternlicht H, Glezerman IG. Hypercalcemia of malignancy and new treatment options. Ther Clin Risk Manag. 2015;11:1779\u201388.","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"9443_CR114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000335676","volume":"5","author":"A Bech","year":"2012","unstructured":"Bech A, Smolders K, Telting D, de Boer H. Cinacalcet for hypercalcemia caused by pulmonary squamous cell carcinoma producing parathyroid hormone-related Peptide. Case Rep Oncol. 2012;5(1):1\u20138.","journal-title":"Case Rep Oncol"},{"issue":"5","key":"9443_CR115","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1590\/2359-3997000000291","volume":"61","author":"H Valdes-Socin","year":"2017","unstructured":"Valdes-Socin H, Almanza MR, Fern\u00e1ndez-Ladreda MT, Daele DV, Polus M, Chavez M, et al. Use of cinacalcet and sunitinib to treat hypercalcaemia due to a pancreatic neuroendocrine tumor. Arch Endocrinol Metab. 2017;61(5):506\u20139.","journal-title":"Arch Endocrinol Metab"},{"key":"9443_CR116","doi-asserted-by":"publisher","unstructured":"Symington M, Davies L, Kaltsas G, Weickert MO. Malignant hypercalcaemia related to parathyroid hormone-related peptide (PTHrP) secretion from a metastatic pancreatic neuroendocrine tumour (NET). BMJ Case Rep. 2017;2017. pii: bcr2017219692 https:\/\/doi.org\/10.1136\/bcr-2017-219692 .","DOI":"10.1136\/bcr-2017-219692"},{"issue":"4","key":"9443_CR117","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/jcpt.12054","volume":"38","author":"YF Shea","year":"2013","unstructured":"Shea YF, Chiu WY, Mok MY, Hung IF, Yau CC. Sunitinib-induced hyperammonaemia in a patient with pancreatic neuroendocrine tumour. J Clin Pharm Ther. 2013;38(4):327\u20139.","journal-title":"J Clin Pharm Ther"},{"issue":"22","key":"9443_CR118","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006874","volume":"96","author":"S Mitani","year":"2017","unstructured":"Mitani S, Kadowaki S, Komori A, Sugiyama K, Narita Y, Taniguchi H, et al. Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy: A case series and review of the literature. Medicine (Baltimore). 2017;96(22):e6874.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"9443_CR119","volume":"6","author":"SA Qureshi","year":"2016","unstructured":"Qureshi SA, Burch N, Druce M, Hattersley JG, Khan S, Gopalakrishnan K, et al. Screening for malnutrition in patients with gastro-entero-pancreatic neuroendocrine tumours: a cross-sectional study. BMJ Open. 2016;6(5):e010765.","journal-title":"BMJ Open"},{"issue":"1","key":"9443_CR120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000442983","volume":"104","author":"S Maasberg","year":"2017","unstructured":"Maasberg S, Knappe-Drzikova B, Vonderbeck D, Jann H, Weylandt KH, Grieser C, et al. Malnutrition Predicts Clinical Outcome in Patients with Neuroendocrine Neoplasia. Neuroendocrinology. 2017;104(1):11\u201325.","journal-title":"Neuroendocrinology"},{"key":"9443_CR121","doi-asserted-by":"publisher","unstructured":"Gallo M, Muscogiuri G, Pizza G, Ruggeri RM, Barrea L, Faggiano A, et al. The management of neuroendocrine tumours: A nutritional viewpoint. Crit Rev Food Sci Nutr. 2017:1\u201312. https:\/\/doi.org\/10.1080\/10408398.2017.1390729 .","DOI":"10.1080\/10408398.2017.1390729"},{"issue":"5","key":"9443_CR122","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.clnu.2017.06.017","volume":"36","author":"J Arends","year":"2017","unstructured":"Arends J, Baracos V, Bertz H, Bozzetti F, Calder PC, Deutz NEP, et al. ESPEN expert group recommendations for action against cancer-related malnutrition. Clin Nutr. 2017;36(5):1187\u201396. https:\/\/doi.org\/10.1016\/j.clnu.2017.06.017 . Review","journal-title":"Clin Nutr"},{"issue":"1","key":"9443_CR123","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1001\/jamainternmed.2017.4361","volume":"178","author":"DJ Morgan","year":"2018","unstructured":"Morgan DJ, Dhruva SS, Coon ER, Wright SM, Korenstein D. 2017 Update on Medical Overuse: A Systematic Review. JAMA Intern Med. 2018;178(1):110\u20135. https:\/\/doi.org\/10.1001\/jamainternmed.2017.4361 .","journal-title":"JAMA Intern Med"},{"issue":"8","key":"9443_CR124","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/ni.3754","volume":"18","author":"L Zitvogel","year":"2017","unstructured":"Zitvogel L, Pietrocola F, Kroemer G. Nutrition, on the risk-benef inflammation and cancer. Nat Immunol. 2017;18(8):843\u201350. https:\/\/doi.org\/10.1038\/ni.3754 .","journal-title":"Nat Immunol"},{"issue":"12","key":"9443_CR125","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2174\/0929867324666170116122915","volume":"24","author":"M Vergati","year":"2017","unstructured":"Vergati M, Krasniqi E, Monte GD, Riondino S, Vallone D, Guadagni F, et al. Ketogenic Diet and Other Dietary Intervention Strategies in the Treatment of Cancer. Curr Med Chem. 2017;24(12):1170\u201385. https:\/\/doi.org\/10.2174\/0929867324666170116122915 .","journal-title":"Curr Med Chem"},{"issue":"3","key":"9443_CR126","doi-asserted-by":"publisher","first-page":"127","DOI":"10.15430\/JCP.2017.22.3.127","volume":"22","author":"HY Chung","year":"2017","unstructured":"Chung HY, Park YK. Rationale, feasibility and acceptability of ketogenic diet for cancer treatment. J Cancer Prev. 2017;22(3):127\u201334. https:\/\/doi.org\/10.15430\/JCP.2017.22.3.127 .","journal-title":"J Cancer Prev"},{"issue":"8","key":"9443_CR127","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s12032-017-0991-5","volume":"34","author":"RJ Klement","year":"2017","unstructured":"Klement RJ. Beneficial effects of ketogenic diets for cancer patients: a realist review with focus on evidence and confirmation. Med Oncol. 2017;34(8):132. https:\/\/doi.org\/10.1007\/s12032-017-0991-5 .","journal-title":"Med Oncol"},{"issue":"5","key":"9443_CR128","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s12032-017-0930-5","volume":"34","author":"N Erickson","year":"2017","unstructured":"Erickson N, Boscheri A, Linke B, Huebner J. Systematic review: isocaloric ketogenic dietary regimes for cancer patients. Med Oncol. 2017;34(5):72. https:\/\/doi.org\/10.1007\/s12032-017-0930-5 .","journal-title":"Med Oncol"},{"issue":"9","key":"9443_CR129","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/ejcn.2016.40","volume":"70","author":"A Lind","year":"2016","unstructured":"Lind A, W\u00e4ngberg B, Elleg\u00e5rd L. Vitamin D and vitamin B12 deficiencies are common in patients with midgut carcinoid (SI-NET). Eur J Clin Nutr. 2016;70(9):990\u20134.","journal-title":"Eur J Clin Nutr"},{"issue":"4","key":"9443_CR130","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1159\/000456619","volume":"105","author":"S Massironi","year":"2017","unstructured":"Massironi S, Zilli A, Bernasconi S, Fanetti I, Cavalcoli F, Ciafardini C, et al. Impact of Vitamin D on the Clinical Outcome of Gastro-Entero-Pancreatic NeuroendocrineNeoplasms: Report on a Series from a Single Institute. Neuroendocrinology. 2017;105(4):403\u201311. https:\/\/doi.org\/10.1159\/000456619 .","journal-title":"Neuroendocrinology"},{"issue":"Suppl 7","key":"9443_CR131","doi-asserted-by":"crossref","first-page":"vii139-54","DOI":"10.1093\/annonc\/mds233","volume":"23","author":"CI Ripamonti","year":"2012","unstructured":"Ripamonti CI, Santini D, Maranzano E, Berti M, Roila F, ESMO Guidelines Working Group. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23(Suppl 7):vii139-54. No abstract available","journal-title":"Ann Oncol"},{"issue":"1","key":"9443_CR132","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s12094-017-1791-2","volume":"20","author":"C. Jara","year":"2017","unstructured":"Jara C, Del Barco S, Gr\u00e1valos C, Hoyos S, Hern\u00e1ndez B, Mu\u00f1oz M, et al. SEOM clinical guideline for treatment of cancer pain (2017). Clin Transl Oncol. 2017; https:\/\/doi.org\/10.1007\/s12094-017-1791-2 .","journal-title":"Clinical and Translational Oncology"},{"issue":"27","key":"9443_CR133","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.2016.68.5206","volume":"34","author":"JA Paice","year":"2016","unstructured":"Paice JA, Portenoy R, Lacchetti C, Campbell T, Cheville A, Citron M, et al. Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical OncologyClinical Practice Guideline. J Clin Oncol. 2016;34(27):3325\u201345. https:\/\/doi.org\/10.1200\/JCO.2016.68.5206 .","journal-title":"J Clin Oncol"},{"issue":"8","key":"9443_CR134","doi-asserted-by":"crossref","first-page":"992","DOI":"10.6004\/jnccn.2013.0119","volume":"11","author":"RA Swarm","year":"2013","unstructured":"Swarm RA, Abernethy AP, Anghelescu DL, Benedetti C, Buga S, Cleeland C, et al. Kumar R; National Comprehensive Cancer Network. Adult Cancer Pain. J Natl Compr Cancer Netw. 2013;11(8):992\u20131022.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"8","key":"9443_CR135","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1200\/JOP.2016.011072","volume":"12","author":"M Li","year":"2016","unstructured":"Li M, Kennedy EB, Byrne N, G\u00e9rin-Lajoie C, Katz MR, Keshavarz H, et al. Management of depression in patients with cancer: a clinical practice guideline. J Oncol Pract. 2016;12(8):747\u201356. https:\/\/doi.org\/10.1200\/JOP.2016.011072 .","journal-title":"J Oncol Pract"},{"issue":"14","key":"9443_CR136","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1002\/cncr.30633","volume":"123","author":"DD Shi","year":"2017","unstructured":"Shi DD, Yuppa DP, Dutton T, Brais LK, Minden SL, Braun IM, et al. Retrospective review of serotonergic medication tolerability in patients with neuroendocrine tumors with biochemically proven carcinoid syndrome. Cancer. 2017;123(14):2735\u201342. https:\/\/doi.org\/10.1002\/cncr.30633 .","journal-title":"Cancer"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11154-018-9443-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-018-9443-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-018-9443-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T22:42:05Z","timestamp":1751409725000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11154-018-9443-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,20]]},"references-count":136,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["9443"],"URL":"https:\/\/doi.org\/10.1007\/s11154-018-9443-6","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,20]]},"assertion":[{"value":"20 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"CJA has received research contracts from Ipsen, Novartis, and ITM Solucin, lecture honorarium from Ipsen, Novartis, and Falk Foundation, and advisory board honorarium from Novartis. CS has received research grants from Novartis, lecture honoraria from Ipsen and Novartis, and advisory board honoraria from Ipsen, Novartis, and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure statements"}},{"value":"The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}